This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Aratana Therapeutics Provides 2013 Development Update

KANSAS CITY, Kan. and BOSTON, Dec. 23, 2013 /PRNewswire/ --  Aratana Therapeutics, Inc. , (Nasdaq: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today provided a year-end update on its development programs.  The company continues to advance each of its small molecule drug candidates within the timelines previously guided and has achieved all planned year-end 2013 clinical milestones.  Aratana remains on track to reach significant inflection points for these programs in 2014 and beyond.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, commented, "We have had an exciting year marked by successful corporate and clinical execution.  As we continue to expand and enhance our pipeline of high-value pet therapeutics, we also remain sharply focused on advancing our clinical programs toward timely approvals.  We are proud to maintain our strong clinical track record by achieving our 2013 milestones, and we look forward to reporting on expected clinical developments for the coming year, which include significant progress in both our dog and cat therapeutic programs."

AT-001 In November, Aratana announced positive top-line data from its pivotal dose-ranging study of AT-001 for dogs, and selected a once-daily dose for further study.  Today, the company provided greater detail on the results of that study:

  • Clinical success rates at day 28 were 61.6% for the selected once-daily dose of AT-001 vs. 42.2% for the placebo group, when compared in a two-group parallel design, which represents a statistically significant difference (p<0.05)
  • Adverse reactions at the selected dose were comparable to the placebo
  • Aratana plans to move AT-001 forward into the pivotal field effectiveness study in 2014, and then, if the results are favorable, into commercialization upon approval, which is anticipated to be in 2016

AT-002 Aratana also announced today that it has initiated the pivotal field effectiveness study for AT-002 in dogs, the company's novel drug candidate for treating inappetence.  

  • The randomized, placebo-controlled, multi-center study is expected to enroll approximately 150 client–owned dogs beginning in January 2014
  • Top-line results are anticipated in the first half of 2015, and the company continues to anticipate potential U.S. approval to be in 2016

In previous studies, laboratory cats and dogs treated with AT-002 exhibited increased food intake and weight gain, and statistically significant results were seen in a dog pilot study of AT-002.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs